Influenza vaccines. A reappraisal of their use

Drugs

Volumn 54, Issue 6, 1997, Pages 841-856

  Palache, Abraham M ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; THEOPHYLLINE; WARFARIN;

ADVERSE DRUG REACTION; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTHRALGIA; ARTHRITIS; ASTHENIA; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FEVER; GUILLAIN BARRE SYNDROME; HEALTH CARE POLICY; HEALTH ECONOMICS; HIGH RISK PATIENT; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; MALAISE; MYALGIA; PREVENTIVE HEALTH SERVICE; PUBLIC HEALTH; REVIEW; SEROLOGY; VACCINATION; VACCINE PRODUCTION; WORLD HEALTH ORGANIZATION;

INFLUENZA VIRUS;

EID: 0030719913     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754060-00004     Document Type: Review

References (228)

1. Cell culture as a substrate for the production of influenza vaccines: memorandum from a WHO meeting [editorial]. Bull WHO 1995; 73: 431-5
2. Ghendon Y. Vaccination against influenza viruses: current status. In: Mizrahi A, editor. Viral vaccines. New York: Wiley-Liss, 1990: 159-201
3. Baum SG. Influenza: a serious epidemic disease that can be prevented Mt Sinai J Med 1990; 57: 225-35
4. Palache AM. Influenza sub-unit vaccine ten years experience. Eur J Clin Res 1992; 3: 117-38
5. Clemens J, Brenner R, Rao M, et al. Evaluating new vaccines for developing countries: efficacy or effectiveness. JAMA 1996; 275: 390-7
6. Fedson DS. Influenza and pneumococcal vaccination of the elderly: newer vaccines and prospects for clinical benefits at the margin. Prev Med 1994; 23: 751-5
7. Spilker B. Guide to clinical trials. New York: Raven Press, 1991; 1-1149
8. Monto AS. The clinical efficacy of influenza vaccination. PharmacoEconomics 1996; 9 Suppl. 3: 16-22
9. Strassburg MA, Greenland S, Sorvillo FJ, et al. Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports. Vaccine 1986; 4: 38-44
10. Keren G, Segev S, Morag A, et al. Failure of influenza vaccination in the aged. J Med Virol 1988; 25: 85-9
11. Phair J, Kauffman CA, Bjornson A. Failure to respond to influenza vaccine in the aged: correlation with B-cell number and function. J Lab Clin Med 1978; 92: 822-8
12. Patriarea PA. A randomized controlled trial of influenza vaccine in the elderly: scientific scrutiny and ethical responsibility. JAMA 1994; 272: 1700-1
13. Govaert TME, Thijs CTMCN, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA 1994; 272: 1661-6
14. Barker WH, Mullooly JP. Influenza vaccination of elderly persons: reduction in pneumonia and influenza hospitalizations and deaths. JAMA 1980; 244: 2547-9
15. Patriarca PA, Weber JA, Parker RA. et al. Efficacy of influenza vaccine in nursing homes: reduction in illness and complications during an influenza A (H3N2) epidemic. JAMA 1985; 253: 1136-9
16. Gross PA, Quinnan GV, Rodstein M, et al. Association of influenza immunization with reduction in mortality in an elderly population: a prospective study. Arch Intern Med 1988; 148: 562-5
17. Saah AJ, Neufeld R, Rodstein M, et al. Influenza vaccine and pneumonia mortality in a nursing home population. Arch Intern Med 1986; 146: 2353-7
18. Serie C, Barme M, Hannoun C, et al. Effects of vaccination on an influenza epidemic in a geriatric hospital. Dev Biol Stand 1977; 39: 317-21
19. Arden NH, Patriarca PA, Kendal AP. Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. In: Kendal AP, Patriarca PA, editors. Options for the control of influenza. New York: Alan R, Liss, 1985: 155-68
20. Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann Intern Med 1995; 123: 518-27
21. Foster DA, Talsma A, Furumoto-Dawson A, et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 1992; 136: 296-307
22. Fedson DS, Wajda A, Nicol JP, et al. Clinical effectiveness of influenza vaccination in Manitoba. JAMA 1993; 270: 1956-61
23. Nichol KL, Margolis KL, Wuorenma J, et al. The efficacy and cost-effectiveness of vaccination against influenza among elderly persons living in the community, N Engl J Med 1994; 331: 778-84
24. Monto AS, Ohmit SE, Foster DA, et al. Case-control study in Michigan on prevention of hospitalization by vaccination, 1989-1991. In: Hannoun C, Kendal AP, Klenk HD, editors. International congress series 1019: options for the control of influenza II. Proceedings of the International Conference on Options of Influenza; 1992 Sep 27-Oct 2; Courchevel. Amsterdam: Excerpta Medica, 1993: 135-41
25. Barker W, Raubertas R, Menegus M, et al. Case control study of influenza vaccine effectiveness in preventing pneumonia hospitalization among older persons, Monroe County. New York, 1989-1992. In: Hannoun C, Kendal AP, Klenk HD, editors. International congress series 1019; options for the control of influenza II. Proceedings of the International Conference on Options of Influenza; 1992 Sep 27-Oct 2: Courchevel. Amsterdam: Excerpta Medica, 1993: 143-51
26. Strikas R, Cook P, Kuller L, et al. Case control study in Ohio and Pennsylvania on prevention of hospitalization by influenza vaccination. In: Hannoun C, Kendal AP, Klenk HD, editors. International congress series 1019: options for the control of influenza II. Proceedings of the International Conference on Options of Influenza; 1992 Sep 27-Oct 2: Courchevel. Amsterdam: Excerpta Medica, 1993: 153-60
27. Palache AM. Influenza vaccination: the effect of dose and age on the antibody response: a methodological evaluation of serological vaccination studies [PhD thesis]. Rotterdam: Erasmus Univ, 1991
28. Fleming DM, Watson JM, Nicholas S, et al. Study of the effectiveness of influenza vaccination in the elderly in the epidemic of 1989-90 using a general practice database, Epidemiol Infect 1995; 115: 581-9
29. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man, Br Med Bull 1979; 35: 69-75
30. Dowdle WR, Coleman MT, Mostow SR, et al. Inactivated influenza vaccines; 2. Laboratory indices of protection. Postgrad Med J 1973; 49: 159-63
31. Hobson D, Baker FA, Curry RL. Effect of influenza vaccines in stimulating antibody in volunteers with prior immunity. Lancet 1973; II:155-6
32. Couch RB, Kasel JA. Immunity to influenza in man. Ann Rev Microbiol 1983; 37: 529-49
33. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines (revision). 1997 Mar 12: CPMP/BWP/214/96
34. Beyer WEP, Palache AM, Osterhaus ADME. Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: a review and metaanalysis of the literature. Clin Drug Invest. In press
35. Glezen WP, Payne AA, Snijder DN, et al. Mortality and influenza. J Infect Dis 1982; 146: 313-21
36. Marine WM. Influenza prevention - the key to reduction in morbidity and mortality from acute respiratory disease (ARD). Am Rev Respir Dis 1987; 136: 546-7
37. Sprenger MJW, Mulder PGH, Beyer WEP, et al. Impact of influenza on mortality in relation to age and underlying disease, 1967-1989. Int J Epidemiol 1993; 22: 334-40
38. Levy E. A cost benefit study of flu vaccination for 25 to 64 year old French people. In: Hannoun C, editor. Options for the control of influenza II. Amsterdam: Elsevier Science, 1993: 47-68
39. Perspectives in disease prevention and health promotion; final results. Medicare influenza vaccine demonstration - selected states, 1988-1992 [editorial]. MMWR Morb Mortality Wkly Rep 1993; 42: 601-4
40. Perez-Tirse J, Gross PA, Review of cost-benefit analyses of influenza vaccine. PharmacoEconomics 1992; 2: 198-206
41. Levy E, Levy P. La vaccination contre la grippe des personnes d'âge actif (25-64 ans): une étude coût-bénéfice. Rev Epidemiol Santé Publique 1992; 40: 285-95
42. Yassi A, Kettner J, Hammond G, et al. Effectiveness and cost-benefit of an influenza vaccination program for health care workers. Can J Infect Dis 1991; 2: 101-8
43. Koplan JP, Axnick NW. Benefits, risks and costs of viral vaccines. Prog Med Virol 1982; 28: 180-91
44. Dejonghe P, Parkinson B. Benefits and costs of vaccination. Vaccine 1992; 10: 936-9
45. Grabenstein JD, Hartzema AG, Guess HA, et al. Community pharmacists as immunization advocates: cost-effectiveness of a cue to influenza vaccination. Med Cure 1992; 30: 503-13
46. Gavira FJ, Lardinois Y. Analisis de rentabilidad de la vacunación antigripal en una población rural (La Victoria, Gordoba). Med Clin (Barc) 1990; 94: 777-81
47. Maucher JM, Gambert SR. Cost-effective analysis of influenza vaccination in the elderly. Age 1990; 13: 81-5
48. Evans DB, Hensley MJ, O'Connor SJ. Influenza vaccination in Australia: a review of the economic evidence for policy recommendations. Med J Aust 1988; 149: 540-3
49. Riddiough MA, Sisk JE, Bell JC. Influenza vaccination: cost-effectiveness and public policy. JAMA 1983; 249: 3186-95
50. Helliwell BE, Drummond MF. The costs and benefits of preventing influenza in Ontario's elderly. Can J Public Health 1988; 79: 175-80
51. Fedson DS. Health economics and the politics of influenza vaccination [abstract]. Options for the control of influenza III. Proceedings of the third International Conference on Options for the Control of Influenza. Cairns, 1996 May 4-9. Amsterdam, Elsevier: 58
52. Demicheli V, Jefferson T. Economic aspects of vaccination. Vaccine 1996; 14: 941-3
53. Hannoun C, editor. The socioeconomics of influenza and influenza vaccination in Europe: proceedings of a symposium sponsored by the European Scientific Working Group on Influenza (ESWI) held in Brussels, 16-18 June 1995. PharmacoEconomics 1996; 9 Suppl. 3: 1-81
54. Palache AM. European Scientific Working Group on Influenza (ESWI). PharmacoEconomics 1996; 9 Suppl. 3: 1-3
55. Szucs TD. What do we not know? What work is required? PharmacoEconomics 1996; 9 Suppl. 3: 79-81
56. Fedson DS. Evaluating the impact of influenza vaccination: issues and methods [abstract]. Options for the control of influenza III. Proceedings of the third International Conference on Options for the Control of Influenza. Cairns, 1996 May 4-9. Amsterdam, Elsevier: 23
57. Fedson DS. Influenza and pneumococcal vaccination in Canada and the United States, 1980-1993: what can the two countries learn from each other? Clin Infect Dis 1995; 20: 1371-6
58. Ives DG, Lave JR, Traven ND, et al. Impact of medicare reimbursement on influenza vaccination rates in the elderly. Prev Med 1994; 23: 134-141
59. Fedson DS, Hannoun C, Leese J, et al. Influenza vaccination in 18 developed countries, 1980-1992. Vaccine 1995; 13: 623-7
60. Nicholson KG. Socioeconomics of influenza and influenza vaccination in Europe. PharmacoEconomics 1996; 9 Suppl. 3: 75-8
61. Szucs TD. The economic impact of influenza in Europe. In: Brown LE, Hampson AW, Webster RG, editors. Options for the control of influenza: III. Proceedings of the third International Conference on Options for the Control of Influenza; Cairns, 1996 May 4-9. Amsterdam: Excerpta Medica. 1996; 34-42
62. Hoskins TW. Assessment of inactivated influenza A vaccine after three outbreaks of influenza A at Christ's Hospital. Lancet 1979; 1: 33-5
63. Hoskins TW, David JR, Smith AJ. Influenza at Christ's Hospital: March 1974. Lancet 1976; I: 105-8
64. Hoskins TW, Davis JR, Allchin A. Controlled trials of inactivated influenza vaccine containing the A/Hong Kong strain during an outbreak of influenza due to the A/England/42/72 strain. Lancet 1973; II: 116-20
65. Gross PA, Denning CR, Gaerlan PF, et al. Benefits of annual influenza immunization in patients with cystic fibrosis, In: Hannoun C, Kendal AP, Klenk HD, editors. International congress series 1019: options for the control of influenza II. Proceedings of the International Conference on Options of Influenza; 1992 Sep 27-Oct 2: Courchevel. Amsterdam: Excerpta Medica, 1993; 417-21
66. Keitel WA, Cate TR, Cough RB. Efficacy of sequential annual vaccination with inactivated influenza virus vaccine. Am J Epidemiol 1998; 127: 353-64
67. Ahmed AH, Nicholson KG, Nguyen-Van-Tam JS. Reduction in mortality associated with influenza vaccine during 1989-90 epidemic. Lancet 1995; 346: 591-5
68. Nicholson KG. Annual vaccination conclusion and recommendation. In: Hannoun C, Kendal AP, Klenk HD, editors. International congress series 1019: options for the control of influenza II. Proceedings of the International Conference on Options of Influenza; 1992 Sep 27-Oct 2: Courchevel. Amsterdam: Excerpta Medica, 1993; 417-21
69. Palache AM, Beyer WEP. Annually repeated influenza vaccination and protection against influenza: a meta-analysis of published literature [abstract]. Options for the control of influenza III. Proceedings of the third International Conference on Options for the Control of Influenza, Cairns, 1996 May 4-9, Amsterdam: Elsevier: 82
70. Prevention and control of influenza: Pt I. Vaccines: recommendations of the advisory committee on immunization practices (ACIP) [editorial], MMWR Morb Mortality Wkly Rep 1994; 43: 1-13
71. Watson JM, Cordier JF, Nicholson KG. Does influenza immunisation cause exacerbations of chronic airflow obstruction or asthma? Thorax 1997; 52: 190-4
72. Bass JW, Roscelli JD. Re: Guillain-Barré syndrome and influenza vaccination in the US army 1980-1988. Am J Epidemiol 1992; 136: 374-6
73. Roscelli JD, Bass JW, Pang L. Guillain-Barré syndrome and influenza vaccination in the US army, 1980-1988. Am J Epidemiol 1991; 952-5
74. Safranek T, Lawrence DN, Kurland LT, et al. Reassessment of the association between Guillain-Barré syndrome and receipt of swine influenza vaccine 1977-1977; results of a two-state study. Am J Epidemiol 1991; 133: 940-51
75. Langmuir AD, Bregman DJ, Kurland LT, et al. An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. Am J Epidemiol 1984; 119: 841-97
76. Kaplan JE, Katona P, Hurwtz ES. Guillain-Barré syndrome in the United States, 1979-1980 and 1980-1981: lack of an association with influenza vaccination. JAMA 1982; 248: 698-700
77. Hurwitz ES, Schonberger LB, Nelson DB. Guillain-Barré syndrome and the 1978-1979 influenza vaccine. N Engl J Med 1981; 304: 1557-61
78. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ. Guillain-Barré syndrome following vaccination in the national influenza immunization program, United States, 1976-1977. Am J Epidemiol 1979; 110: 105-23
79. D'Arcy PF. More about theophylline and influenza vaccination. Pharm Int 1985; 242-3
80. Bukowskyj M, Munt PW, Wigle R, et al. Theophylline clearance: lack of effect of influenza vaccination and ascorbic acid. Am Rev Respir Dis 1984; 129: 672-5
81. Hannan SE, May JJ, Pratt DS, et al. The effect of whole virus influenza vaccination on theophylline pharmacokinetics. Am Rev Respir Dis 1988; 137: 903-6
82. Jonkman JHG, Upton RA. Pharmacokinetic drug interactions with theophylline. Clin Pharmacokinet 1984; 9: 309-34
83. Jonkman JHG, Wymenga ASC, de Zeeuw RA, et al. No effect of influenza vaccination on theophylline pharmacokinetics as studied by ultraviolet spectrophotometry HPLC, and emit assay methods. Ther Drug Monitor 1988; 10: 345-48
84. Stults BM, Hashisaki PA. Influenza vaccination and theophylline pharmacokinetics in patients with chronic obstructive lung disease. West J Med 1983; 139: 651-4
85. Bussey HJ, Saklad JJ. Effect of influenza vaccine on chronic warfarin therapy, Drug Intell Clin Pharm 1988; 22: 198-201
86. Gomolin JH. Lack of effect of influenza vaccine on warfarin anticoagulation in the elderly. Can Med Assoc J 1986; 135: 39-41
87. Weibert RT, Lorentz SM, Norcross WA, et al. Effect of influenza vaccine in patients receiving long-term warfarin therapy. Clin Pharm 1986; 5: 499-503
88. Gomolin IH. Lack of effect of influenza vaccine on warfarin anticoagulation in the elderly. Can Med Assoc J 1986; 135: 39-41
89. Raj G, Kumar R, McKinney WP. Safety of intramuscular influenza immunization among patients receiving long-term warfarin anticoagulation therapy. Arch Intern Med 1995; 155: 1529-31
90. Quellette JJ, Reed CE. Increased response of asthmatic subjects to methacholine after influenza vaccine. Allergy 1965; 36: 558-63
91. Bierman CW, Shapiro GG, Pierson WE, et al. Safety of influenza vaccination in allergic children. J Infect Dis 1977; 136 Suppl.: S652-5
92. Bell TD, Chai H, Berlow B, et al. Immunization with killed influenza virus in children with chronic asthma. Chest 1978; 73: 140-5
93. de Jongste JC, Degenhart HJ, Neyens HJ, et al. Bronchial responsiveness and leucocyte reactivity after influenza vaccine in asthmatic patients. Eur J Respir Dis 1984; 65: 196-200
94. Campbell BG, Edwards RL. Safety of influenza vaccination in adults with asthma. Med J Aust 1984; 773-5
95. Murphy KR, Strunk RC. Safe administration of influenza vaccine in asthmatic children hypersensitive to egg proteins. J Pediatr 1985; 106: 931-3
96. Stenius-Aariala B, Huttunen JK, Phylala R, et al. Lack of clinical exacerbations in adults with chronic asthma after immunization with killed influenza virus. Chest 1986; 6: 786-9
97. Albazzaz MK, Harvey JE, Grilli EA, et al. Subunit influenza vaccination in adults with asthma: effect on clinical state, airway reactivity, and antibody response. BMJ 1987; 294: 1196-7
98. Hassan WU, Henderson AF, Keaney NP. Influenza vaccination in asthma [letter]. Lancet 1992; 339: 194
99. Ong ELC. Influenza and asthma. Lancet 1992; 339: 367-8
100. Palache AM, v d Velden JW, Influenza vaccination in asthma [letter]. Lancet 1992; 339: 741
101. Daggett P. Influenza and asthma [letter]. Lancet 1992; 339: 367
102. Fox R, French N, Davies L, et al. Influenza immunization status and viral respiratory tract infections in patients with chronic airflow limitation. Respir Med 1995; 89: 559-61
103. Rothbarth PH, Kempen BM, Sprenger MJW. Sense and nonsense of influenza vaccination in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 151: 1682-6
104. Grabenstein JD. Drug interactions involving immunologic agents: Pt 1. Vaccine-immunoglobulin, and vaccine drug interactions. Ann Pharmacother 1990; 24: 67-81
105. Renton KW, Gray JD, Hall RL. Decreased elimination of theophylline after influenza vaccination. Can Med Assoc J 1980; 123: 288-90
106. Walker S, Schreiber L, Middelkamp JN. Serum theophylline levels after influenza vaccination [letter]. Can Med Assoc J 1981; 125: 243-4
107. Meredith CG, Christian CD, Johnson RF, et al. Effects of influenza virus vaccine on hepatic drug metabolism. Clin Pharmacol Ther 1985; 37: 396-401
108. Kramer P, Tsuru M, Cook CE, et al. Effect of influenza vaccine on warfarin anticoagulation. Clin Pharmacol Ther 1984; 35: 416-8
109. Farrow PR, Nicholson KG. Lack of effect of influenza and pneumococcal vaccines on anticoagulation by warfarin. J Infect 1984; 9: 157-60
110. Winstanley PA, Tjia J, Back DJ, et al. Lack of effect of highly purified subunit influenza vaccination on theophylline metabolism. Br J Clin Pharmacol 1985; 20: 47-53
111. Anand SC, Itkin IH, Kind LS. Effect of influenza vaccine on methacholine (mecholyl) sensitivity in patients with asthma of known and unknown origin. J Allergy 1968; 42: 187-92
112. Banks J, Bevan C, Fennerly A, et al. Association between rise in antibodies and increase in airway sensitivity after intramuscular injection of killed influenza virus in asthmatic patients. Eur J Resp Dis 1985; 66: 268-72
113. Kava T, Laitinen LA. Effects of killed and live attenuated influenza vaccine on symptoms and specific airway conductance in asthmatics and healthy subjects. Allergy 1985; 40: 42-7
114. McIntosh K, Foy HM, Modlin JF, et al. Multi-center two-dose trials of bivalent influenza A vaccines in asthmatic children aged six to eighteen years. J Inf Dis 1977; 136 Suppl.: S645-7
115. Bell TD, Leffert F, McIntosh K. Monovalent influenza A/New Jersey/76 virus vaccines in asthmatic children: pulmonary function and skin tests for allergy. J Infect Dis 1977; 136 Suppl.: S612-5
116. Ghirga G, Ghirga P, Rodino P, et al. Safety of the subunit influenza vaccine in asthmatic children. Vaccine 1991; 9: 913-4
117. Committee on Issues and Priorities for New Vaccine Development. Prospects for immunizing against influenza viruses A and B. In: New vaccine development: establishing priorities. National Academy Press, 1985; 342-64
118. Monto AS, Sullivan KM. Acute respiratory illness in the community: frequency of illness and the agents involved. Epidemiol Infect 1993; 110: 145-60
119. Glezen WP, Decker M, Joseph SW, et al. Acute respiratory disease associated with influenza epidemics in Houston, 1981-1983. J Infect Dis 1987; 155: 1119-26
120. Kondo S, Abe K. The effects of influenza virus infection FEV1 in asthmatic children: the time-course study. Chest 1991; 100: 1235-8
121. Minor TE, Dick EC, De Meo AN, et al. Viruses as precipitants of asthmatic attacks in children, JAMA 1974; 227: 292-8
122. Beasley R, Coleman ED, Hermon Y, et al. Viral respiratory tract infection and exacerbations of asthma in adult patients. Thorax 1988; 43: 679-83
123. Lin CY, Kuo YC, Liu WT, et al. Immunomodulation of influenza virus infection in the precipitating asthma attack. Chest 1993; 6: 1235-8
124. Philit F, Etienne J, Calvet A, et al. Agents infectieux associés aux décompensations des bronchopathies chroniques obstructives et aux attaques d'asthme, Rev Mal Resp 1992; 9: 191-6
125. Glezen WP. Morbidity associated with the major respiratory viruses, Pediatr Ann 1990; 19: 535-42
126. Couch RB, Kasel JA, Glezen WP, et al. Influenza: its control in persons and populations. J Infect Dis 1986; 153: 431-40
127. Minor TE, Dick EC, Baker JW, et al. Rhinoviruses and influenza type A infections as precipitants of asthma. Am Rev Resp Dis 1976; 113: 149-53
128. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbation of asthma in adults. BMJ 1993; 307: 982-6
129. Mertsola J, Ziegler T, Ruuskanen O, et al. Recurrent wheezy bronchitis and viral respiratory infections. Arch Dis Child 1991; 66: 124-9
130. Nicholson KG, Snacken R, Pulache AM. Influenza immunisation policies in Europe and the United States. Vaccine 1995; 13 (4): 365-9
131. Margolis KL, Nichol KL, Poland GA, Pluhar RE. Frequency of adverse reactions to influenza vaccination in the elderly. JAMA 1990; 264: 1139-41
132. LaMontagne JR, Noble GR, Quinnan GV, et al. Summary of clinical trials of inactivated influenza vaccine-1978. Rev Infect Dis 1983; 5: 723-36
133. Margolis KL, Nichol KL, Poland GA, et al. Frequency of adverse reactions to influenza vaccine in the elderly: a randomized, placebo controlled trial. JAMA 1990; 264: 1139-41
134. Palache AM, Beyer WEP, Sprenger MJW, et al. Antibody response after influenza immunization with various vaccine doses: a double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers. Vaccine 1993; 11: 3-9
135. Govaert TME, Dinant GJ, Aretz K, et al. Adverse reactions to influenza vaccine in elderly people: randomised double-blind placebo controlled trial. BMJ 1993; 307: 988-90
136. Beyer WEP, Palache AM, Kerstens R, et al. Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of fourteen independent studies. Eur J Clin Microbiol Infect Dis 1996; 15: 65-70
137. Setia U, Serventi I, Lorenz P. Factors affecting the use of influenza vaccine in the institutionalized elderly. J Am Geriatr Soc 1985; 33: 856-8
138. Nichol KL, Lofgren RP, Capinski J. Influenza vaccination. Knowledge, attitudes, and behavior among high-risk outpatients. Arch Intern Med 1992; 152: 106-10
139. Rose G. The strategy of preventive medicine. Oxford: Oxford Medical Publications, 1993
140. Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol 1980; 112: 798-811
141. Fedson DS, Wajda A, Nicol JP, et al. Disparity between influenza vaccination rates and risks for influenza-associated hospital discharge and death in Manitoba in 1982-1983. Ann Intern Med 1992; 116: 550-5
142. Wiselka MJ, Nicholson KG, Kent J, Stern M. Influenza and asthma. Lancet 1992; 339: 367-8
143. Aymard M, Cox NJ, Dubois G, et al. Recommendations of the 7th European meeting of influenza and its prevention. Eur J Epidemiol 1994; 10: 525-6
144. Palache AM, Brands R, van Scharrenburg GJM. Immunogenicity and reactogenicity of influenza subunit vaccines produced either in Madin Darby Kidney (MDCK) cells or in fertilised chicken eggs. J Infect Dis 1997; 176 Suppl. 1; S20-3
145. Clements ML, O'Donnell S, Levine MM, et al. Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus. Infect Immun 1983; 40: 1044-51
146. Powers D, Sears SD, Murphy BR, et al. Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines. J Clin Microbiol 1989; 27: 2666-71
147. Ada GL, Jones PD. The immune response to influenza infection. In: Current topics in microbiology and immunology. Berlin: Springer-Verlag, 1986: 1-54
148. Rimmelzwaan GF, Osterhaus ADME. Cytotoxic T lymphocyte memory: role in cross-protective immunity against influenza? Vaccine 1995; 13: 703-5
149. Good MF. Harnessing cytotoxic T lymphocytes for vaccine design. Lancet 1995; 345: 999-1000
150. McMichael A. Cytotoxic T lymphocytes specific for influenza virus. Curr Topics Microbiol Immunol 1994; 189: 75-91
151. Ada GL. What to expect of a good vaccine and how to achieve it. Vaccine 1988; 6: 77-9
152. Ott G, Barchfeld GL, Van Nest G. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine 1995; 13: 1557-62
153. Tamura S, Asanuma H, Tomita T, et al. Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine. Vaccine 1994; 12: 1083-9
154. Holmgren J, Lycke N, Czerkinsky C. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine 1943; 11: 1179-84
155. Keitel W, Couch R, Bond N, et al. Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine 1993; 11: 909-13
156. Wilson AD, Robinson A, Irons L, et al. Adjuvant action of cholera toxin and pertussis toxin in the induction of IgA antibody response to orally administered antigen. Vaccine 1993; 11: 113-8
157. Masihi KN, Rohde-Schulz B, Masek K, et al. Antiviral and adjuvant activity of immunomodulator adamantylamide dipeptide. Microbiol Infections 1992; 275-86
158. Beyer WEP, Noordzij TC, Kramer P, et al. Effect of immunomodulator thymopentin on impaired seroresponse to influenza vaccine in patients on haemodialysis. Nephron 1990; 54: 296-301
159. Byars NE, Allison AC, Harmon MW, et al. Enhancement of antibody response to influenza B virus haemagglutinin by use of a new adjuvant formulation. Vaccine 1990; 8: 49-56
160. Maeda H, Saiki I, Ishida H, et al. Adjuvant activities of synthetic lipid A subunit analogues and its conjugates with muramyl dipeptide derivates. Vaccine 1989; 7: 275-81
161. Tamura S, Samegai Y, Kurata H, et al. Enhancement of protective antibody response by cholera toxin B subunit inoculated intranasally with influenza vaccine. Vaccine 1989; 7: 257-62
162. Clements ML, Makhene MK, Karron RA, et al. Effective immunization with live attenuated infuenza A virus can be achieved in early infancy. J Infect Dis 1996; 173: 44-51
163. Gorse GJ, Campbell MJ, Otto EE, et al. Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically III elderly with live attenuated or inactivated influenza virus vaccine. J Infect Dis 1995; 172: 1-10
164. Keitel WA, Couch RB, Quarles JM, et al. Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults. J Infect Dis 1993; 167: 305-11
165. Treanor JJ, Mattison R, Dumyati G, et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Am Coll Phys 1992; 117: 623-33
166. Clements ML, Snyder MH, Sears SD, et al. Evaluation of the infectivity, immunogenicity, and efficacy of live cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in adult volunteers. J Infect Dis 1990; 161: 869-77
167. Keitel WA, Couch RB, Cate TR, et al. Cold recombinant influenza B/Texas/1/84 vaccine virus (CRB 87): attenuation. immunogenicity, and efficacy against homotypic challenge. J Infect Dis 1990; 161: 22-6
168. Karron RA, Steinhoff MC, Subbarao EK,et al. Safety and immunogenicity of a cold-adapted influenza A (hINI) reassortant virus vaccine administered to infants less than 6 months of age. Pediatr Infect Dis J 1995; 14: 10-6
169. Hocart M, Grajower M, Donabedian A, et al. Preparation and characterization of a purified influenza virus neuraminidase vaccine. Vaccine 1995; 13: 1793-8
170. Johnasson BE, Price PM, Kilbourne ED. Immunogenicity of influenza A virus N2 neuraminidase produced in insect larvac by baculovirus recombinants. Vaccine 1995; 13: 841-5
171. Kilbourne ED, Couch RB, Kasel JA, et al. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine 1995; 13: 1799-803
172. Johansson BE, Grajower B, Kilbourne ED. Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice. Vaccine 1993; 11: 1037-9
173. Johansson BE, Bucher DJ, Kilbourne ED. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J Virol 1989; 63: 1239-46
174. de Haan A, Geerligs HJ, Huchshorn JP, et al. Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes. Vaccine 1995; 13: 155-62
175. Aramaki Y, Fujii Y, Yachi K, et al. Activation of systemic and mucosal immune response following nasal administration of liposomes. Vaccine 1994; 12: 1241-5
176. Friede M, Muller S, Briand JP, et al. Selective induction of protection against influenza virus infection in mice by a lipidpeptide conjugate delivered in liposomes. Vaccine 1994; 12: 791-7
177. Ott S, Wunderli-Allenspach H. Liposomes and influenza viruses as an in vitro model for membrane interactions: I. Kinetics of membrane fusion and lipid transfer. Eur J Pharm Sci 1994; 1: 323-32
178. Gregoriadis G, Tan L, Ben-Ahmeida ETS, et al. Liposomes enhance the immunogenicity of reconstituted influenza virus A/PR/8 envelopes and the formation of protective antibody by influenza virus A/Sichuan/87 (H3N2) surface antigen. Vaccine 1992; 10: 747-53
179. Mbawuike IN, Wyde PR, Anderson PM. Enhancement of the protective efficacy of inactivated influenza A virus vaccine in aged mice by IL-2 liposomes. Vaccine 1990; 8: 347-52
180. Guink NE, Kris RM, Goodman-Snitkoff G, et al. Intranasal immunization with proteoliposomes protects against influenza. Vaccine 1989; 7: 147-51
181. Richards RL, Hayre MD, Hockmeyer WT, et al. Liposomes, lipid A, and aluminum hydroxide enhance the immune response to a synthetic malaria sporozoite antigen. Infect Immun 1988; 56: 682-6
182. Kaji M, Kaji Y, Ohkuma K, et al. Phase I clinical tests of influenza MDP-virosome vaccine (KD-5382). Vaccine 1992; 10: 663-7
183. Glück R. Immunopotentiating reconstituted influenza virosomes (IRIVs) and other adjuvants for improved presentation of small antigens. Vaccine 1992; 10: 915-9
184. Morein B, Simons K. Subunit vaccines against enveloped viruses: virosomes, micelles and other protein complexes. Vaccine 1985; 3: 83-93
185. Glück R, Mischler R, Finkel B, et al. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 1994; 344: 160-3
186. Ben Ahmeida ETS, Gregoriadis G, Potter CW, et al. Immunopotentiation of local and systemic humoral immune response by ISCOMs, liposomes and FCA: role in protection against influenza A in mice. Vaccine 1993; 11: 1302-9
187. Pyle SW, Morein B, Bess JW, et al. Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HIV-1) or the HIV-1 external envelope glycoprotein (gp 120). Vaccine 1989; 7: 465-73
188. Trudel M, Nadon F, Seguin C, et al. Experimental polyvalent ISCOMs subunit vaccine induces antibodies that neutralize human and bovine respiratory syncytial virus. Vaccine 1989; 7: 12-6
189. Kersten GFA, van de Put AM, Teerlink T, et al. Immunogenicity of liposomes and Iscoms containing the major outer membrane protein of Neisseria gonorrhoeae: influence of protein content and liposomal bilayer composition, Infect Immun 1988; 56: 1661-4
190. Morein B. The Iscom antigen-presenting system. Nature 1988; 332: 287-8
191. Sundquist B, Lovgren K, Morein B, Influenza virus iscoms: antibody response in animals. Vaccine 1988; 6: 49-53
192. Nashar TO, Amin T, Marcello A, et al. Current progress in the development of the B subunits of cholera toxin and Escherichia coli heat-labile enterotoxin as carriers for the oral delivery of heterologous antigens and epitopes. Vaccine 1993; 11: 235-40
193. Lewis DJM, Castello-Branco LRR, Novotny P, et al. Circulating cellular immune response to oral immunization of humans with cholera toxin B-subunit. Vaccine 1993; 11: 119-21
194. Tamura S, Funato H, Nagamine T, et al. Effectiveness of cholera toxin B subunit as an adjuvant for nasal influenza vaccination despite pre-existing immunity to CTB. Vaccine 1989; 7: 503-5
195. Ben-Yehuda A, Ehleiter D, Hu A, et al. Recombinant vaccinia virus expressing the PR/8 influenza hemagglutinin gene overcomes the impaired immune
196. Vanlandschoot P, Maertens G, Min Jou W, et al. Recombinant secreted haemagglutinin protects mice against a lethal challenge of influenza virus. Vaccine 1993; 11: 1185-7
197. Stitz L, Schmitz C, Binder D, et al. Characterization and immunological properties of influenza A virus nucleoprotein (NP): cell-associated NP isolated from infected cells or viral NP expressed by vaccinia recombinant virus do not confer protection. J Gen Virol 1990; 71: 1169-79
198. Leclerc C, Charbit A, Molla A, et al. Antibody response to a foreign epitope expressed at the surface of recombinant bacteria: importance of the route of immunization. Vaccine 1989; 7: 242-8
199. Tite JP, Russell SM, Dougan G, et al. Antiviral immunity induced by recombinant nucleoprotein of influenza A virus: I. Characteristics and cross-reactivity of T cell responders. J Immunol 1988; 141: 3980-7
200. Fynan EF, Webster RG, Fuller DH, et al. DNA vaccines: a novel approach to immunization. Int J Immunopharmacol 1995; 17: 79-83
201. Donnelly JJ, Friedman A, Martinez D, et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nature Med 1995; 1: 583-7
202. McDonnell WM, Askari FK. Molecular medicine: DNA vaccines. N Engl J Med 1996; 334: 42-3
203. Morris W, Steinhoff MC, Russell PK. Potential of polymer microencapsulation technology for vaccine innovation. Vaccine 1994; 12: 5-11
204. Walker RI. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 1994; 12: 387-400
205. Gruber WC, Hinson HP, Holland KL, et al. Comparative trial of large-particle aerosol and nose drop administration of live attenuated influenza vaccines. J Infect Dis 1993; 168: 1282-5
206. Moldoveanu Z, Novak M, Huang WQ, et al. Oral immunization with influenza virus in biodegradable microspheres. J Infect Dis 1993; 167: 84-90
207. O'Hagan DT, McGree JP, Holmgren J, et al. Biodegradable microparticles for oral immunization. Vaccine 1993; 11: 149-54
208. O'Hagan DT. Oral delivery of vaccines. Formulation and clinical pharmacokinetic considerations. Clin Pharmacokinet 1992; 22: 1-10
209. Eldridge JH, Staas JK, Meulbroek JA, et al. Biodegradable microspheres as a vaccine delivery system. Mol Immunol 1991; 28: 287-94
210. Johansson BE, Kilbourne ED. Comparison of intranasal and aerosol infection of mice in assessment of immunity to influenza virus infection. J Virol Methods 1991; 35: 109-14
211. O'Hagan DT, Jeffery H, Roberts MJJ, et al. Controlled release microparticles for vaccine development. Vaccine 1991; 9: 768-71
212. Bergmann KC, Waldman RH. Oral immunization with influenza virus: experimental and clinical studies. In: Current topics in microbiology and immunology 146th ed. Berlin: Springer-Verlag, 1989: 83-9
213. Betts RF, Morrow PE, Utell MJ, et al. Prophylaxis of viral respiratory infection with aerosolized vaccine. J Aerosol Med 1989; 2: 239-45
214. Chen KS, Quinnan GV. Efficacy of inactivated influenza vaccine delivered by oral administration. In: Current topics in microbiology and immunology. 146th ed. Berlin: Springer-Verlag, 1989: 101-6
215. Moldoveanu Z, Staas JK, Gilley RM, et al. Immune responses to influenza virus in orally and systematically immunized mice. In: Current topics in microbiology and immunology. 146th ed. Berlin: Springer-Verlag, 1989: 91-9
216. Murphy BR, Clements ML. The systemic and mucosal immune response of humans to influenza A virus. In: Current topics in microbiology and immunology. 146th ed. Berlin: Springer-Verlag, 1989: 107-16
217. Farag-Mahmed FI, Wyde PR, Rosborough JP, et al. Immunogenicity and efficacy of orally administered inactivated influenza virus vaccine in mice. Vaccine 1988; 6: 262-8
218. Kimura M, Kuno-Sakia H, Takesue R, et al. Nasal application of inactivated influenza vaccine. Acta Paediatr Jpn 1988; 30: 601-3
219. Mestecky J. The common mucosal immune system and current strategies for induction of immune response in external secretions. J Clin Immunol 1987; 7: 265-76
220. Waldman RH, Stone J, Bergmann KC, et al. Secretory antibody following oral influenza immunization. Am J Med Sci 1986; 292: 367-71
221. Brands R, Palache AM, van Scharrenburg GJM. Madin Darby Canine Kidney (MDCK)-cells for the production of inactivated influenza subunit vaccine: safety characteristics and clinical results in the elderly. In: Brown LE, Hampson AW, Webster RG, editors. Options for the control of influenza: III. Proceedings of the third International Conference on Options for the Control of Influenza: 1996 May 4-9; Cairns. Amsterdam: Excerpta Medica, 1996: 683-93
222. Rowe PM. Pandemic influenza (un)preparedness described [news item]. Lancet 1995; 346: 1699
223. Marwick C. Readiness is all: public health experts draft plan outlining pandemic influenza response. JAMA 1996; 275: 179-80
224. Martin JT. Enhanced immunogenicity of Chiron Biocine adjuvanted influenza vaccine in the elderly. In: Brown LE, Hampson AW, Webster RG, editors. Options for the control of influenza: III. Proceedings, of the 3rd International Conference on Options for the Control of Influenza; 1996 May 4-9: Cairns. Amsterdam: Excerpta Medica, 1996: 647-52
225. Waldman RH, Bergmann KC. Introduction to oral immunization against viral infections. In: Current topics in microbiology and immunology. 146th ed. Berlin: Springer-Verlag, 1989: 69-72
226. Waldman RH, Bergmann KC, Stone J, et al. Age-dependent antibody response in mice and humans following oral influenza immunization. J Clin Immunol 1987; 7: 327-32
227. Clements ML, Betts RF, Tierney EL, et al. Comparison of inactivated and live influenza A virus vaccines. In: Kendal AP, Patriarca PA, eds. Options for the control of influenza. New York: Alan R. Liss, 1986: 243-53
228. Gupta RK, Relyveld EH, Lindblad EB, et al. Adjuvants a balance between toxicity and adjuvanticity. Vaccine 1993; 11: 293-306